Method of utilizing biosynthesis and chemical modification technology in producing thymic hormone al monomer

A chemical modification and biosynthesis technology, applied in the fields of biosynthesis and chemical modification, can solve the problems of high cost of thymosin α1, many toxic reagents, and difficulty in large-scale implementation, and achieve the convenience of large-scale production, low production cost, and high technology simple effect
CN1388133AInactive Publication Date: 2003-01-01吴建中
0 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
吴建中
Publication Date
2003-01-01
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

The present invention belongs to the field of biosynthesis and chemical modification technology. By means of bioengineering process, several thymosin genes are recombined and the recombinant gene is expressed in host cell to obtain high-expression thymosin fusion body. The fusion body is cracked and modified chemically to form thymosin alpha 1 monomer finally. The production process can produce thymosin alpha 1 identical with that produced chemically and is simple, low in cost and suitable for production in large scale. The present invention also provides the production process of several thymosin alpha 1 derivatives.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biosynthesis and chemical modification, and particularly relates to a production method of thymosin α1 for improving human immunity and treating various diseases. Background technique

[0002] Thymosin α1 was discovered as early as 1977. It is a 28 amino acid acidic small molecular polypeptide, which was originally isolated from thymus. There have been extensive and in-depth studies on its physiological effects. Whether it is in vivo or in vitro analysis, it shows a strong stimulating effect on the immune system of the body, promotes the maturation of T lymphocytes, and is an immune enhancement factor of T lymphocytes. Clinically, it can be applied to the adjuvant treatment of many diseases related to the immune system, such as hepatitis B, hepatitis C, cancer, immunodeficiency, low immunity, and AIDS.

[0003] At present, the pure product of thymosin α1 is a chemical drug, which has been listed both at...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More